The effervescent Hall of Fame catcher whose single for the Mets in the 1986 World Series touched off one of the most improbable rallies in baseball, died Thursday. The Kid was 57.
Carter was diagnosed with a malignant brain tumor last May, two weeks after finishing his second season as coach at Palm Beach Atlantic University. Mets spokesman Jay Horwitz said Carter died at a hospice in the West Palm Beach, Fla., area.
Courtesy of the Associated Press
Agreement finalizes plans to market Loratadine products.
Drug Week February 21, 2003 2003 FEB 21 – (NewsRx.com & NewsRx.net) — Andrx Corporation (ADRX) and Perrigo Company (PRGO) announced that they have entered into a multiyear agreement whereby Andrx will manufacture and supply Perrigo with loratadine/pseudoephedrine 5/120 mg, loratadine rapidly disintegrating, and loratadine/pseudoephedrine 10/240 mg tablets (generic versions of Claritin-D 12 Hour, Claritin RediTabs, and Claritin-D 24 Hour, respectively), which Perrigo will market as over-the-counter (OTC) products.
Andrx originally submitted abbreviated new drug applications (ANDAs) for these products as prescription drugs, but the U.S. Food and Drug Administration (FDA) recently granted the Claritin line of products OTC status.
Andrx believes that its bioequivalent version of Claritin-D 24 Hour will enjoy a 180-day period of market exclusivity and anticipates receiving final FDA marketing approval on this product after its over-the-counter product labeling is approved. Andrx expects to receive final FDA marketing approval on its bioequivalent versions of Claritin-D 12 Hour and Claritin RediTabs following the expiration of the exclusivity periods of other generic manufacturers. go to website loratadine side effects this web site loratadine side effects
Larry Rosenthal, Andrx Pharmaceuticals executive vice president of sales and marketing, commented, “With the FDA decision to allow Claritin to go over-the-counter, Andrx looked for a way to maximize the value of its generic line of products by partnering with an experienced OTC marketer. We are pleased to be working with Perrigo, the nation’s largest provider of store brand over- the-counter pharmaceuticals. Their marketing expertise is renowned in the store brand arena, which should position Andrx for a strong first-showing into the OTC class of products.” Perrigo executive vice president, Mark Olesnavage, stated, “We are looking forward to providing these important new allergy products to the store brand market and are pleased to partner with Andrx, a leader in developing the technologies necessary for these dosage forms. The alliance with Andrx provides Perrigo the quickest path to market for these three products and reinforces our leadership role in bringing critical Rx to OTC switches to the store brand market.” Perrigo anticipates the first shipments of the 24-hour sustained-release product to begin in mid-2003.
This article was prepared by Drug Week editors from staff and other reports.
Deja tu comentario
